Ritobegron

Summary

Ritobegron (CHEMBL2107773) is a phase-3 clinical-stage small molecule; indicated across 2 conditions including overactive bladder.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 2 conditions
• Clinical trials: 3
• Chemistry: 373.4 Da · C21H27NO5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2107773
Name	Ritobegron
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	9820882
Molecular formula	C21H27NO5
Molecular weight	373.4
InChIKey	VMMYRRFPMAGXNP-BTYIYWSLSA-N

SMILES: CC1=CC(=C(C=C1OCC(=O)O)C)CCN[C@@H](C)[C@@H](C2=CC=C(C=C2)O)O

IUPAC name: 2-[4-[2-[[(1R,2S)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]-2,5-dimethylphenoxy]acetic acid

Also known as: Kuc-7483, KUC-7483, Ritobegron, RITOBEGRON, ritobegron

Patent coverage: 57 distinct patent families (146 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
overactive bladder	3	MONDO:0006624	EFO:1000781

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
PHASE3	2
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01003405	PHASE3	WITHDRAWN	Long-term Safety and Efficacy of KUC-7483 in Patients With Overactive Bladder
NCT01004315	PHASE3	COMPLETED	A Confirmatory Study of KUC-7483 in Patients With Overactive Bladder
NCT00742833	PHASE2	COMPLETED	A Phase II Study of KUC-7483 in Patients With Overactive Bladder

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).